Cytomegalovirus DNA load monitoring in stool specimens for anticipating the occurrence of intestinal acute graft‐versus‐host disease following allogeneic hematopoietic stem cell transplantation: Is it of any value?
Felipe Bueno,Eliseo Albert,Estela Giménez,José Luis Piñana,Ariadna Pérez,María Dolores Gómez,Juan Carlos Hernández‐Boluda,Eva María Gonzalez‐Barberá,Juan Montoro,Manuel Guerreiro,Aitana Balaguer‐Roselló,Rafael Hernani,Jaime Sanz,Carlos Solano,David Navarro
DOI: https://doi.org/10.1111/tid.13440
2020-08-16
Transplant Infectious Disease
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Data have been published suggesting a bidirectional interaction between Cytomegalovirus (CMV) infection and acute Graft versus Host Disease (aGvHD) in allogeneic hematopoietic stem cell transplant (allo‐HSCT) recipients. Here, we hypothesized that prospective CMV DNA monitoring in stool specimens may be useful for predicting subsequent occurrence of Intestinal aGvHD (IaGvHD).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>This two‐center study enrolled 121 consecutive adult patients undergoing any modality of allo‐HSCT. A total of 1,009 stool specimens were collected (a median of 7 specimens/patient; range, 1‐18). CMV DNA monitoring in stools and plasma was performed using real‐time PCR assays.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>CMV DNA was detected in stools in 20 patients (cumulative incidence, 16.9%; 95% CI, 6.3‐31.8%). Median CMV DNA level in stool specimens was 1,258 IU/0.1g (range, 210‐4,087 IU/0.1 g). All these patients and their donors were CMV seropositive, and 16 of the 20 patients also had CMV DNAemia, while 4 patients had CMV DNA detected in stools without CMV DNAemia. No correlation was found between CMV DNA loads in plasma and stools (<i>P </i>=0.40). Prior CMV DNAemia, aGvHD, or IaGvHD were not associated with presence of CMV DNA in feces. IaGvHD was present in 30 patients, in 5 of whom CMV DNA was detected in stools. Neither detection of CMV DNA in feces nor in plasma was associated with subsequent IaGvHD (OR, 0.67; 95% CI, 0.18‐2.52; <i>P </i>=0.55 and OR, 0.86; 95% CI, 0.38‐1.96<i>; P </i>=0.71, respectively). No patient in this cohort had CMV end‐organ disease within the study period. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>Our study failed to provide evidence pointing to a reciprocal interaction between GI CMV infection and IaGvHD. CMV DNA monitoring in stools seems of no value to anticipate occurrence of IaGvHD.</p></section>
immunology,infectious diseases,transplantation